Clinical trials: Early Stage Parkinson Disease
Parkinson's Disease
Detection of A-synuclein Aggregate as Biomarker in Diagnosing Parkinson's Disease at Early Stage by Using Protein Misfolding Cyclic Amplification (PMCA)
The study will investigate the biomarker of a-synuclein aggregate in CSF detected by protein misfolding cyclic amplification (PMCA) and its sensitivity and specificity in diagnosing Parkinson's disease at H-Y stage I and disease…
- Trial name
- NCT04536857
- Testing
- Biomarker assay
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Huashan Hospital
Parkinson's Disease
Study of Parkinson's Early Stage With Deferiprone
The goal of this study is to evaluate the effects of deferiprone, an iron-chelating drug, in patients with Parkinson's disease. Participants will be randomized to receive one of four different dosages of deferiprone or placebo…
- Trial name
- SKY (NCT02728843)
- Testing
- Deferiprone
- Where
- 20 sites in Canada, France and 2 more
- Volunteers
- 140 people
- Sponsor
- ApoPharma
Parkinson's Disease (PD), Parkinson Disease 6, Early-Onset
Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's Disease
This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical trial designed to evaluate the efficacy, safety, and Pop PK characteristics of TJ0113 Capsules in treating EOPD patients.
- Trial name
- NCT07741045
- Testing
- TJ0113 200mg, TJ0113 400mg
- Where
- 21 sites in China
- Volunteers
- 300 people
- Sponsor
- Hangzhou PhecdaMed Co., Ltd.
Parkinson Disease
A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease
This study is a fixed dose, dose response study to characterize the dose response for ropinirole PR in early stage PD patients (Hoehn \& Yahr stages I-III).
- Trial name
- TANDEM-662 (NCT01485172)
- Testing
- ropinirole monotherapy
- Where
- 34 sites in United States, Estonia and 3 more
- Volunteers
- 186 people
- Sponsor
- GlaxoSmithKline
Parkinson Disease
Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease
The purpose of this study is to assess the efficacy, the safety, and the effect on biomarkers of 2 dose levels of oral GT-02287 over placebo after 48 weeks of treatment in treated and untreated participants with early PD.
- Trial name
- NCT07280299
- Testing
- Low Dose GT-02287, High Dose GT-02287
- Volunteers
- 111 people
- Sponsor
- Gain Therapeutics, Inc.
Parkinson's Disease
Tolerability and Safety of Subcutaneous Administration of Two Doses of AFFITOPE® PD01A in Early Parkinson's Disease
This is a phase I study to assess the tolerability and safety of 4 injections of two different doses of AFFITOPE® PD01A formulated with an adjuvant to patients with early Parkinson's disease in male and female patients aged 45 to…
- Trial name
- NCT01568099
- Testing
- AFFITOPE® PD01A, Control
- Where
- Austria
- Volunteers
- 32 people
- Sponsor
- Affiris AG
Parkinson's Disease
Study of Urate Elevation in Parkinson's Disease, Phase 3
A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial to determine whether oral inosine dosed to moderately elevate serum urate (from ≤5.7 mg/dL to 7.1-8.0 mg/dL) over 2 years slows clinical decline in early…
- Trial name
- SURE-PD3 (NCT02642393)
- Testing
- Inosine
- Where
- 62 sites in United States, Puerto Rico
- Volunteers
- 298 people
- Sponsor
- Michael Alan Schwarzschild
Early Stage Parkinson's Disease
SLV308 for Treatment of Patients With Early Parkinson's Disease
This study is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 administered as a monotherapy in patients with early stage PD.
- Trial name
- NCT00269516
- Testing
- pardoprunox
- Where
- 128 sites in United States, Argentina and 19 more
- Volunteers
- 468 people
- Sponsor
- Solvay Pharmaceuticals
Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline
Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.
This study aims to evaluate the efficacy of community-based early detection and targeted interventions, including stem cell therapy and wearable non-invasive brain-computer interface (BCI) devices, for Mild Cognitive Impairment…
- Conditions
- Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis
- Trial name
- MCITestCare (NCT07214974)
- Testing
- Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Noah Tech, Corp.
Parkinson
Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)
Opicapone (OPC) is a third generation catechol O methyltransferase (COMT) inhibitor (COMTi) developed by BIAL-Portela \& Cª, S.A.
- Trial name
- EPSILON (NCT04978597)
- Testing
- Opicapone 50 mg
- Where
- Bulgaria
- Volunteers
- 410 people
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with…
- Trial name
- PARAISO (NCT07174310)
- Testing
- Prasinezumab
- Where
- 192 sites in United States, Australia and 15 more
- Volunteers
- 900 people
- Sponsor
- Hoffmann-La Roche
Parkinson's Disease
Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease
The purpose of this study is to characterize the pharmacokinetics (PK) of LY03003 following multiple escalating intramuscular injections, as compared to Neupro patch and to evaluate the safety and tolerability and preliminary…
- Trial name
- 03003MAD (NCT02055274)
- Testing
- LY03003, Neupro
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Luye Pharma Group Ltd.
Parkinson's Disease
A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy
This study will investigate the effect of TCH346 compared to placebo in delaying the need for symptomatic treatment with dopaminergic agents
- Trial name
- NCT00407212
- Testing
- TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)
- Where
- 45 sites in United States, Brazil and 7 more
- Volunteers
- 301 people
- Sponsor
- Novartis
Parkinson's Disease
A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease
A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease.
- Trial name
- NCT06175767
- Testing
- MT101-5
- Volunteers
- 120 people
- Sponsor
- Mthera Pharma Co., Ltd.
Oxidative Stress is an Important Cause of Parkinson's Disease
Idebenone Treatment of Early Parkinson's Diseasesymptoms
On May 30,2018 ,Investigators intend to conduct a multicenter, randomized, double-blind, placebo-controlled study of idebenone in the treatment of early-stage Parkinson's disease with motor and non-motor symptoms which is to…
- Trial name
- ITEP (NCT03727295)
- Volunteers
- 180 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Parkinson Disease, Occupational Therapy
Effectiveness of Online Program and Task-related Training for Parkinson's Disease
The goal of this clinical trial is to compare the effectiveness of online self-management program and on-site task-related training for people with early stage Parkinson's disease.
- Conditions
- Parkinson Disease, Occupational Therapy, Telerehabilitation, Activities of Daily Living
- Trial name
- NCT06248073
- Testing
- on-line self-management training, onsite task-related training
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Chang Gung University
Parkinson Disease
Identification of Motor Symptoms Related to Parkinson's Disease Using Motion Tracking Sensors at Home
Parkinson's disease (PD) is a chronic and progressive neurological movement disorder, meaning that symptoms continue and worsen over time. Nearly 10 million people worldwide are living with Parkinson's disease.
- Trial name
- KÄVELI (NCT03366558)
- Testing
- UPDRS questionnaires, 20-step walking test
- Where
- Finland
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Satakunta Central Hospital
Parkinson Disease
A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale
In this study, researchers will learn more about a study drug called BIIB122 in participants with early-stage Parkinson's disease (PD). The study will focus on participants with a specific genetic variant in their LRRK2 gene.
- Trial name
- LIGHTHOUSE (NCT05418673)
- Testing
- BIIB122
- Where
- 27 sites in United States, France and 4 more
- Volunteers
- 7 people
- Sponsor
- Biogen
Parkinson Disease (PD), Idiopathic Parkinson's Disease
Assessment of the Safety, Immunogenicity, and Pharmacodynamics of TRB-001 in Patients With Early Idiopathic Parkinson's Disease
This is a randomized, placebo-controlled, double-blind, dose-finding phase 1b study with the purpose to assess the safety, immunogenicity and pharmacodynamics of TRB-001 in early idiopathic Parkinson's Disease patients.
- Trial name
- NCT07840027
- Testing
- TRB-001
- Where
- Austria
- Volunteers
- 36 people
- Sponsor
- Tridem Bioscience FlexCo
Parkinsons Disease
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on…
- Trial name
- PADOVA (NCT04777331)
- Testing
- Prasinezumab
- Where
- 110 sites in United States, Austria and 7 more
- Volunteers
- 586 people
- Sponsor
- Hoffmann-La Roche